Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst Sung Ji Nam maintains a Sector Outperform rating on Pacific Biosciences but lowers the price target from $8 to $7.
August 28, 2024 | 2:48 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Scotiabank has maintained its Sector Outperform rating for Pacific Biosciences but has reduced the price target from $8 to $7, indicating a slightly less optimistic outlook.
The maintenance of a Sector Outperform rating suggests continued confidence in Pacific Biosciences' performance relative to its sector peers. However, the lowered price target from $8 to $7 indicates a tempered outlook on the stock's potential upside, which could lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100